Newron Pharmaceuticals SpA (FRA:NP5) Cyclically Adjusted FCF per Share: €-0.86 (As of Dec. 2025)


FRA:NP5 Newron Pharmaceuticals SpA FRA:NP5
64 GF Score
Price €12.65
GF Value €13.96
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Newron Pharmaceuticals SpA Cyclically Adjusted FCF per Share?

Newron Pharmaceuticals SpA FRA:NP5 -0.78% 64 Cyclically Adjusted FCF per Share is €-0.86 as of Dec. 2025. GuruFocus rates FRA:NP5 with a GF Score™ of 64/100 and a GF Value™ of €13.96 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Newron Pharmaceuticals SpA's adjusted free cash flow per share data for the fiscal year that ended in Dec. 2025 was €1.618. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.86 for the trailing ten years ended in Dec. 2025.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 12.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 0.30% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 11.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Newron Pharmaceuticals SpA was 26.10% per year. The lowest was -7.20% per year. And the median was 16.00% per year.

As of today (2026-07-12), Newron Pharmaceuticals SpA's current stock price is € 12.65. Newron Pharmaceuticals SpA's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec. 2025 was €-0.86. Newron Pharmaceuticals SpA's Cyclically Adjusted Price-to-FCF of today is .


Newron Pharmaceuticals SpA  (FRA:NP5) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Newron Pharmaceuticals SpA Cyclically Adjusted FCF per Share Related Terms


Newron Pharmaceuticals SpA Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Newron Pharmaceuticals SpA's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Newron Pharmaceuticals SpA Cyclically Adjusted FCF per Share Chart

Newron Pharmaceuticals SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.81 -1.07 -1.20 -1.07 -0.86

Newron Pharmaceuticals SpA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.20 0.00 -1.07 0.00 -0.86

FRA:NP5 vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Newron Pharmaceuticals SpA's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Newron Pharmaceuticals SpA Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Newron Pharmaceuticals SpA's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Newron Pharmaceuticals SpA's Cyclically Adjusted Price-to-FCF falls into.


FRA:NP5
64GF Score
Newron Pharmaceuticals SpA FRA:NP5
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Newron Pharmaceuticals SpA Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Newron Pharmaceuticals SpA's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=1.618/122.6000*122.6000
=1.618

Current CPI (Dec. 2025) = 122.6000.

Newron Pharmaceuticals SpA Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201612 -1.338 100.300 -1.635
201712 -0.519 101.200 -0.629
201812 -0.896 102.300 -1.074
201912 -1.234 102.800 -1.472
202012 -0.875 102.600 -1.046
202112 -0.642 106.600 -0.738
202212 -0.623 119.000 -0.642
202312 -0.569 119.700 -0.583
202412 -0.857 121.200 -0.867
202512 1.618 122.600 1.618

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.86 mean?
Newron Pharmaceuticals SpA (FRA:NP5) has a Cyclically Adjusted FCF per Share of €-0.86 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Newron Pharmaceuticals SpA and its competitors.
Is Newron Pharmaceuticals SpA's Cyclically Adjusted FCF per Share too high?
Newron Pharmaceuticals SpA's current Cyclically Adjusted FCF per Share is €-0.86. Overall, Newron Pharmaceuticals SpA has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Newron Pharmaceuticals SpA's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Newron Pharmaceuticals SpA's Cyclically Adjusted FCF per Share of €-0.86 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Newron Pharmaceuticals SpA and its competitors. Newron Pharmaceuticals SpA's current Cyclically Adjusted FCF per Share is €-0.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Newron Pharmaceuticals SpA stock overvalued right now?
Based on GuruFocus' analysis, Newron Pharmaceuticals SpA (FRA:NP5) is currently considered Fairly Valued. The stock's GF Value™ is €13.96, compared to a current price of €12.65 — trading 9.4% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.86. Newron Pharmaceuticals SpA's overall GF Score™ is 64/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Newron Pharmaceuticals SpA (FRA:NP5), the current Cyclically Adjusted FCF per Share is €-0.86 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Newron Pharmaceuticals SpA (FRA:NP5) Overvalued in 2026?

Based on GuruFocus' analysis, Newron Pharmaceuticals SpA stock appears to be undervalued. The current stock price of €12.65 is trading 9.4% below its estimated GF Value™ of €13.96. GuruFocus considers Newron Pharmaceuticals SpA to be Fairly Valued.

Key valuation signals for FRA:NP5:

  • Cyclically Adjusted FCF per Share: €-0.86
  • GF Value™: €13.96 vs. price of €12.65 (9.4% below fair value)
  • GF Score™: 64/100 with 5 warning signs

No single metric tells the full story. See the FRA:NP5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Newron Pharmaceuticals SpA Business Description

Address Via Antonio Meucci 3, Bresso, Milan, ITA, 20091
Newron Pharmaceuticals SpA is a Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinson's disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Geographically the research and development activities are performed in Italy and the United States.
64GF Score

Get the complete analysis for FRA:NP5

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€12.65
Price
€13.96
GF Value